Key Points
- Director Ezra Friedberg sold 558 Pelthos Therapeutics shares at an average price of $20.72, generating $11,561.76. The transaction, conducted under a Rule 10b5-1 plan, reduced his ownership by 0.69% to 80,484 shares.
- Pelthos shares opened at $21.48 and remain well below their 52-week high of $37.50. The clinical-stage biopharmaceutical reported a quarterly loss of $6.62 per share on $15.60 million in revenue and has sharply negative profitability metrics.
- Analysts maintain a “Moderate Buy” consensus, with five Buy ratings and one Hold and an average price target of $55.40. Institutional investors own approximately 77.96% of the company.
Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) Director Ezra Friedberg sold 558 shares of the firm's stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $20.72, for a total transaction of $11,561.76. Following the transaction, the director directly owned 80,484 shares in the company, valued at $1,667,628.48. The trade was a 0.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pelthos Therapeutics Price Performance
Shares of NYSEAMERICAN:PTHS opened at $21.48 on Wednesday. The company has a 50-day simple moving average of $24.61 and a 200-day simple moving average of $25.20. Pelthos Therapeutics Inc. has a one year low of $18.19 and a one year high of $37.50. The company has a debt-to-equity ratio of 3.40, a quick ratio of 1.31 and a current ratio of 1.98. The stock has a market capitalization of $82.27 million, a price-to-earnings ratio of -0.98 and a beta of 3.07.
Pelthos Therapeutics (NYSEAMERICAN:PTHS - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share (EPS) for the quarter. The company had revenue of $15.60 million for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. On average, analysts predict that Pelthos Therapeutics Inc. will post -15.22 EPS for the current year.
Wall Street Analysts Forecast Growth
Separately, Oppenheimer dropped their target price on Pelthos Therapeutics from $66.00 to $64.00 and set an "outperform" rating on the stock in a report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $55.40.
Read Our Latest Stock Analysis on PTHS
Institutional Trading of Pelthos Therapeutics
An institutional investor recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE increased its position in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Free Report) by 59.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,919 shares of the company's stock after purchasing an additional 4,819 shares during the period. Pale Fire Capital SE owned approximately 0.38% of Pelthos Therapeutics worth $271,000 as of its most recent SEC filing. Institutional investors and hedge funds own 77.96% of the company's stock.
About Pelthos Therapeutics
(
Get Free Report)
Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company's work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.
Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.
Publicly available information about the company's specific product pipeline, operating history, geographic reach and leadership is limited.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
